Fakuade Funsho Emmanuel

Fakuade Funsho Emmanuel

Auto-generated profile, based on publicly available information

Fakuade Funsho Emmanuel

Institute of Pharmacology and Toxicology (J.R.D.P., F.E.M., F.E.F., D.B., P.B., P.J.S., K.R., S.K., N.V.), University Medical Center Göttingen, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2023 in Basic Research in Cardiology
Verified
Journal Article
Open access
PDF file
FSFitzwilliam Seibertz
Fitzwilliam Seibertz
Henry SutantoHenry Sutanto
Henry Sutanto
RDRebekka Dülk
Rebekka Dülk
JPJulius Ryan D. Pronto
Julius Ryan D. Pronto
RSRobin Springer
Robin Springer
NVNiels Voigt
Niels Voigt
Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly used for personalised medicine and preclinical cardiotoxicity testing. Reports on hiPSC-CM commonly describe heterogenous functional readouts and underdeveloped or immature phenotypical properties. Cost-effective, fully defined monolayer culture is approaching mainstream adoption; however, the optimal age at which to utilise hiPSC-CM is unknown. In this study, we identify, track and model the dynamic developmental behaviour of key ionic currents and Ca2+-handling properties in hiPSC-CM over long-term culture (30–80 days). hiPSC-CMs > 50 days post differentiation show significantly larger ICa,L density along with an increased ICa,L-triggered Ca2+-transient. INa and IK1 densities significantly increase in late-stage cells, contributing to increased upstroke velocity and reduced action potential duration, respectively. Importantly, our in silico model of hiPSC-CM electrophysiological age dependence confirmed IK1 as the key ionic determinant of action potential shortening in older cells. We have made this model available through an open source software interface that easily allows users to simulate hiPSC-CM electrophysiology and Ca2+-handling and select the appropriate age range for their parameter of interest. This tool, together with the insights from our comprehensive experimental characterisation, could be useful in future optimisation of the culture-to-characterisation pipeline in the field of hiPSC-CM research.

13 August 2024 in Circulation
Verified
Journal Article
Open access
FFFunsho E. Fakuade
Funsho E. Fakuade
DHDominik Hubricht
Dominik Hubricht
VMVanessa Möller
Vanessa Möller
ISIzzatullo Sobitov
Izzatullo Sobitov
ALAiste Liutkute
Aiste Liutkute
NVNiels Voigt
Niels Voigt
BACKGROUND: Alterations in the buffering of intracellular Ca 2+ , for which myofilament proteins play a key role, have been shown to promote cardiac arrhythmia. It is interesting that although studies report atrial myofibrillar degradation in patients with persistent atrial fibrillation (persAF), the intracellular Ca 2+ buffering profile in persAF remains obscure. Therefore, we aimed to investigate the intracellular buffering of Ca 2+ and its potential arrhythmogenic role in persAF. METHODS: Transmembrane Ca 2+ fluxes (patch-clamp) and intracellular Ca 2+ signaling (fluo-3-acetoxymethyl ester) were recorded simultaneously in myocytes from right atrial biopsies of sinus rhythm (Ctrl) and patients with persAF, alongside human atrial subtype induced pluripotent stem cell–derived cardiac myocytes (iPSC-CMs). Protein levels were quantified by immunoblotting of human atrial tissue and induced pluripotent stem cell–derived cardiac myocytes. Mouse whole heart and atrial electrophysiology were measured on a Langendorff system. RESULTS: Cytosolic Ca 2+ buffering was decreased in atrial myocytes of patients with persAF because of a depleted amount of Ca 2+ buffers. In agreement, protein levels of selected Ca 2+ binding myofilament proteins, including cTnC (cardiac troponin C), a major cytosolic Ca 2+ buffer, were significantly lower in patients with persAF. Small interfering RNA (siRNA)–mediated knockdown of cTnC (si-cTNC) in atrial iPSC-CM phenocopied the reduced cytosolic Ca 2+ buffering observed in persAF. Si-cTnC treated atrial iPSC-CM exhibited a higher predisposition to spontaneous Ca 2+ release events and developed action potential alternans at low stimulation frequencies. Last, indirect reduction of cytosolic Ca 2+ buffering using blebbistatin in an ex vivo mouse whole heart model increased vulnerability to tachypacing-induced atrial arrhythmia, validating the direct mechanistic link between impaired cytosolic Ca 2+ buffering and atrial arrhythmogenesis. CONCLUSIONS: Our findings suggest that loss of myofilament proteins, particularly reduced cTnC protein levels, causes diminished cytosolic Ca 2+ buffering in persAF, thereby potentiating the occurrence of spontaneous Ca 2+ release events and atrial fibrillation susceptibility. Strategies targeting intracellular buffering may represent a promising therapeutic lead in persAF management.

7 November 2025 in Circulation Research
Verified
Journal Article
Open access
JPJulius Ryan D. Pronto
Julius Ryan D. Pronto
FMFleur E. Mason
Fleur E. Mason
EREva A Rog-Zielinska
Eva A Rog-Zielinska
FFFunsho E. Fakuade
Funsho E. Fakuade
DBDonata Bülow
Donata Bülow
NVNiels Voigt
Niels Voigt
BACKGROUND: Mitochondrial calcium (Ca 2+ ) is a key regulator of cardiac energetics by stimulating the tricarboxylic acid cycle during elevated workload. Atrial fibrillation (AF) is associated with a reduction in cytosolic Ca 2+ transient amplitude, but its effect on mitochondrial Ca 2+ handling and cellular redox state has not been explored. METHODS: Cardiac myocytes isolated from patient-derived right atrial biopsies were subjected to workload transitions using patch-clamp stimulation and β-adrenergic stimulation (isoproterenol). In conjunction, nicotinamide adenine dinucleotide (phosphate)/flavin adenine dinucleotide (NAD[P]H/FAD) autofluorescence, cytosolic and mitochondrial [Ca 2+ ] were monitored using epifluorescence microscopy. Sarcoplasmic reticulum and mitochondria were imaged using electron microscopy and tomography and stimulated emission depletion microscopy. The effects of the mitochondrial Ca 2+ uptake enhancer ezetimibe on proarrhythmic activity in atrial myocytes and on AF burden in patients were investigated. RESULTS: Mitochondrial Ca 2+ accumulation during increased workload was blunted in AF, and was associated with impaired regeneration of nicotinamide adenine dinucleotide and flavin adenine dinucleotide. Nanoscale imaging revealed spatial disorganization of sarcoplasmic reticulum and mitochondria, associated with microtubule destabilization. This was confirmed in human induced pluripotent stem cell–derived cardiac myocytes, where treatment with the microtubule destabilizer nocodazole displaced mitochondria and increased proarrhythmic Ca 2+ sparks, which were rescued by MitoTEMPO. Ezetimibe also reduced the occurrence of arrhythmogenic Ca 2+ release events both in AF myocytes and nocodazole-treated human induced pluripotent stem cell–derived cardiac myocytes. Retrospective patient analysis also revealed a reduced AF burden in patients on ezetimibe treatment. CONCLUSIONS: Mitochondrial Ca 2+ uptake and accumulation are impaired in atrial myocytes from patients with AF. The disturbed spatial association between sarcoplasmic reticulum and mitochondria driven by destabilized microtubules may underlie impaired Ca 2+ transfer in AF. Enhancing mitochondrial Ca 2+ uptake potentially protects against arrhythmogenic events.

7 July 2023 in Circulation Research
Verified
Journal Article
Closed access
YDYuanyuan Dai
Yuanyuan Dai
NINadezda Ignatyeva
Nadezda Ignatyeva
HXHang Xu
Hang Xu
RWRuheen Wali
Ruheen Wali
KTKarl Toischer
Karl Toischer
AEAntje Ebert
Antje Ebert
Background: Systemic defects in intestinal iron absorption, circulation, and retention cause iron deficiency in 50% of patients with heart failure. Defective subcellular iron uptake mechanisms that are independent of systemic absorption are incompletely understood. The main intracellular route for iron uptake in cardiomyocytes is clathrin-mediated endocytosis. Methods: We investigated subcellular iron uptake mechanisms in patient-derived and CRISPR/Cas–edited induced pluripotent stem cell–derived cardiomyocytes as well as patient-derived heart tissue. We used an integrated platform of DIA-MA (mass spectrometry data-independent acquisition)–based proteomics and signaling pathway interrogation. We employed a genetic induced pluripotent stem cell model of 2 inherited mutations ( TnT [ troponin T ]-R141W and TPM1 [ tropomyosin 1 ]-L185F) that lead to dilated cardiomyopathy (DCM), a frequent cause of heart failure, to study the underlying molecular dysfunctions of DCM mutations. Results: We identified a druggable molecular pathomechanism of impaired subcellular iron deficiency that is independent of systemic iron metabolism. Clathrin-mediated endocytosis defects as well as impaired endosome distribution and cargo transfer were identified as a basis for subcellular iron deficiency in DCM-induced pluripotent stem cell–derived cardiomyocytes. The clathrin-mediated endocytosis defects were also confirmed in the hearts of patients with DCM with end-stage heart failure. Correction of the TPM1-L185F mutation in DCM patient–derived induced pluripotent stem cells, treatment with a peptide, Rho activator II, or iron supplementation rescued the molecular disease pathway and recovered contractility. Phenocopying the effects of the TPM1-L185F mutation into WT induced pluripotent stem cell–derived cardiomyocytes could be ameliorated by iron supplementation. Conclusions: Our findings suggest that impaired endocytosis and cargo transport resulting in subcellular iron deficiency could be a relevant pathomechanism for patients with DCM carrying inherited mutations. Insight into this molecular mechanism may contribute to the development of treatment strategies and risk management in heart failure.

25 August 2025 in The Journal of Physiology
Verified
Journal Article
Open access
ISIzzatullo Sobitov
Izzatullo Sobitov
KRKatharina Ritzenhoff
Katharina Ritzenhoff
MGMarie Gaulrapp
Marie Gaulrapp
LBLea Becker
Lea Becker
ALAiste Liutkute
Aiste Liutkute
NVNiels Voigt
Niels Voigt
Blebbistatin is an excitation–contraction uncoupling agent commonly used in cardiac optical mapping; however, it has been reported to influence cardiac myofilament Ca2+ sensitivity. As primary contributors to Ca2+ buffering within cardiomyocytes, cardiac myofilaments play a critical role, and even minor disruptions in intracellular Ca2+ buffering significantly alter the free Ca2+ concentration. In this study, we investigated the effect of blebbistatin, a myosin II ATPase inhibitor, on intracellular Ca2+ buffering and cellular electrophysiology in induced pluripotent stem cell‐derived atrial cardiomyocytes. Simultaneous whole‐cell ruptured patch‐clamp and fluorescence microscopy techniques were used to assess intracellular Ca2+ handling, in addition to automated high‐throughput patch‐clamp to investigate ion channel function. Comprehensive analysis of Ca2+ buffering revealed that blebbistatin (10 µmol/l) causes a significant increase in buffer dissociation constant, suggesting decreased affinity of Ca2+ buffers. Furthermore, systolic and diastolic Ca2+ levels, sarcoplasmic reticulum Ca2+ leak and the incidence of spontaneous Ca2+ release events were significantly higher upon blebbistatin treatment. Although there was lack of impact on INa and ICa,L peak density, Ca2+‐dependent inactivation of ICa,L was significantly enhanced, and IK1 density was significantly smaller after blebbistatin. Importantly, these effects were reversed after chelation of intracellular Ca2+ with EGTA. Our observations indicate that blebbistatin reduces Ca2+ buffering, which, in turn, causes changes in cellular electrophysiology in cardiomyocytes. image Key points: Intracellular Ca2+ buffering plays an important role in determining Ca2+ dynamics in cardiomyocytes. Blebbistatin, an excitation–contraction uncoupling agent widely used in experimental studies, decreases the affinity of intracellular Ca2+ buffers, as indicated by an increased buffer dissociation constant. Blebbistatin leads to higher systolic and diastolic Ca2+ levels and increased sarcoplasmic reticulum Ca2+ leak. Blebbistatin enhances L‐type Ca2+ current (ICa,L) Ca2+‐dependent inactivation and reduces inward rectifier potassium current (IK1) density, while INa and ICa,L remain unchanged. The effects of blebbistatin are mitigated by chelation of intracellular Ca2+ with EGTA, showing that they are secondary to altered Ca2+ buffering.

8 October 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
FFFunsho E Fakuade
Funsho E Fakuade
JGJana Grune
Jana Grune
NVNiels Voigt
Niels Voigt
Role of autoantibodies against atrial and ventricular ion channels in cardiac arrhythmias and their therapeutic potential. Autoantibodies targeting various cardiac ion channels can have inhibitory (−) and stimulatory (+) effects on depolarizing (purple: INa,peak and ICa,L) and repolarizing (green: IK) ion currents, contributing to pathogenesis of various cardiac arrhythmias, including atrial fibrillation (AF). Additionally, autoantibodies may offer opportunities to develop specific and personalized antiarrhythmic therapeutic approaches. For a detailed explanation, please refer to the text. INa,peak, peak sodium current; ICa,L, L-type-calcium current; IK, potassium current; QTc, corrected QT-interval; Tdp, Torsades de pointes tachycardia.